Pfizer shares rose early Tuesday due to higher than expected demand for its COVID vaccine, but quickly sunk 2.3% after ...
Pfizer's fourth quarter beat expectations on strong sales of its Covid vaccine and pill, bolstering its sales as it seeks to ...
The results cap off a critical year for Pfizer, which has been slashing costs as it recovers from the rapid decline of its ...
EXECUTIVE COMMENTARY Dr. Albert Bourla, Chairman and Chief Executive Officer, stated: “2024 was a strong year of execution and performance for Pfizer in which we met or exceeded our strategic and ...